Éric Charpentier

2.9k total citations
22 papers, 1.0k citations indexed

About

Éric Charpentier is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Éric Charpentier has authored 22 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Éric Charpentier's work include Multiple Myeloma Research and Treatments (10 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Éric Charpentier is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Éric Charpentier collaborates with scholars based in United States, France and Spain. Éric Charpentier's co-authors include Michael Danso, Denise A. Yardley, Eric P. Winer, Ravi Vij, Nikoletta Lendvai, Joseph Mıkhael, Don M. Benson, Karl Hsu, Thomas G. Martin and Rachid Baz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.

In The Last Decade

Éric Charpentier

22 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Éric Charpentier United States	15	652	401	372	186	178	22	1.0k
Parul Doshi United States	19	787 1.2×	568 1.4×	745 2.0×	454 2.4×	116 0.7×	49	1.6k
Hyung‐Gyoon Kim United States	17	405 0.6×	541 1.3×	121 0.3×	197 1.1×	189 1.1×	33	1.0k
Paola Storti Italy	17	546 0.8×	460 1.1×	515 1.4×	233 1.3×	119 0.7×	54	961
Satyen H. Gohil United Kingdom	14	343 0.5×	546 1.4×	116 0.3×	278 1.5×	226 1.3×	30	966
Katarina Luptakova United States	14	698 1.1×	521 1.3×	460 1.2×	183 1.0×	52 0.3×	50	1.1k
Christina Krupka Germany	13	861 1.3×	398 1.0×	502 1.3×	594 3.2×	46 0.3×	25	1.3k
Kenneth Wen United States	16	787 1.2×	570 1.4×	740 2.0×	427 2.3×	39 0.2×	52	1.3k
Vikas A. Gupta United States	17	641 1.0×	1.0k 2.5×	926 2.5×	198 1.1×	82 0.5×	76	1.6k
Victoria M. Garbitt United States	8	461 0.7×	932 2.3×	729 2.0×	155 0.8×	202 1.1×	16	1.3k
Oday Hamid United States	15	685 1.1×	669 1.7×	57 0.2×	175 0.9×	123 0.7×	41	1.2k

Countries citing papers authored by Éric Charpentier

Since Specialization

Citations

This map shows the geographic impact of Éric Charpentier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Charpentier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Charpentier more than expected).

Fields of papers citing papers by Éric Charpentier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Charpentier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Charpentier. The network helps show where Éric Charpentier may publish in the future.

Co-authorship network of co-authors of Éric Charpentier

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Charpentier. A scholar is included among the top collaborators of Éric Charpentier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Charpentier. Éric Charpentier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Charpentier, Éric, et al.. (2023). Transcriptomic Analysis Reveals the Inability of Recombinant AAV8 to Activate Human Monocyte-Derived Dendritic Cells. International Journal of Molecular Sciences. 24(13). 10447–10447. 2 indexed citations

Mıkhael, Joseph, Joshua Richter, Ravi Vij, et al.. (2020). A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia. 34(12). 3298–3309. 37 indexed citations

Dièras, Véronique, Hervé Bonnefoi, Emilio Alba, et al.. (2019). Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. Breast Cancer Research and Treatment. 177(2). 383–393. 12 indexed citations

Martin, Thomas G., Stephen A. Strickland, Martha Glenn, et al.. (2019). Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer Journal. 9(4). 41–41. 70 indexed citations

Bézie, Séverine, Dimitri Meistermann, Stéphanie Kilens, et al.. (2018). Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/− Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice. Frontiers in Immunology. 8. 2014–2014. 55 indexed citations

Picarda, Élodie, Séverine Bézie, Stéphanie Kilens, et al.. (2017). Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells. JCI Insight. 2(3). e90088–e90088. 37 indexed citations

Legrand, Nolwenn, Catherine Willem, Gaëlle David, et al.. (2017). Killer Immunoglobulin-Like Receptor Allele Determination Using Next-Generation Sequencing Technology. Frontiers in Immunology. 8. 547–547. 19 indexed citations

Martin, Thomas G., Rachid Baz, Don M. Benson, et al.. (2017). A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 129(25). 3294–3303. 134 indexed citations

Bell‐McGuinn, Katherine M., Jason Konner, William P. Tew, et al.. (2016). A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. International Journal of Gynecological Cancer. 26(2). 255–260. 6 indexed citations

10.

Clayton, Nicholas P., et al.. (2016). Sargramostim Accelerates Leukocyte Recovery and Improves Mortality Rate at Day 60 in a Non-Human Primate Model of Hematopoietic Acute Radiation Syndrome When Administered 48 h after Total Body Irradiation. Blood. 128(22). 2512–2512. 9 indexed citations

11.

Vij, Ravi, Nikoletta Lendvai, Thomas G. Martin, et al.. (2016). A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.. Journal of Clinical Oncology. 34(15_suppl). 8009–8009. 14 indexed citations

12.

Charpentier, Éric, Pierre Lindenbaum, Olivier Pichon, et al.. (2015). Search for Rare Copy-Number Variants in Congenital Heart Defects Identifies Novel Candidate Genes and a Potential Role for FOXC1 in Patients With Coarctation of the Aorta. Circulation Cardiovascular Genetics. 9(1). 86–94. 29 indexed citations

13.

Martin, Thomas G., Joshua Richter, Ravi Vij, et al.. (2015). A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. Blood. 126(23). 509–509. 26 indexed citations

14.

Karakachoff, Matilde, Nicolas Duforet-Frebourg, Floriane Simonet, et al.. (2014). Fine-scale human genetic structure in Western France. European Journal of Human Genetics. 23(6). 831–836. 23 indexed citations

15.

Baz, Rachid, Don M. Benson, Nikoletta Lendvai, et al.. (2014). A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood. 124(21). 83–83. 32 indexed citations

16.

O’Shaughnessy, Joyce, Lee Schwartzberg, Michael Danso, et al.. (2014). Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology. 32(34). 3840–3847. 229 indexed citations

17.

Martin, Thomas G., Karl Hsu, Stephen A. Strickland, et al.. (2014). A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.. Journal of Clinical Oncology. 32(15_suppl). 8532–8532. 44 indexed citations

18.

Hsu, Karl, Éric Charpentier, Ravi Vij, et al.. (2014). A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 32(15_suppl). 8512–8512. 16 indexed citations

19.

Llombart‐Cussac, Antonio, Aňa Lluch, Cristian Villanueva, et al.. (2012). SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 30(15_suppl). 1011–1011. 7 indexed citations

20.

O’Shaughnessy, J., Lee S. Schwartzberg, Michael Danso, et al.. (2011). A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 29(15_suppl). 1007–1007. 192 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact